BreakingBusiness & Finance
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment
International homepage April 6, 2026 at 02:47 AM

Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
Original source
International homepage



